Answers are grounded in this paper and cite their sources.
This editorial highlights the ALLHAT trial findings that thiazide diuretics should be the preferred initial therapy for hypertension due to their superior effectiveness and lower cost.
Quite simply, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is one of the most important trials of antihypertensive therapy. For decades, experts have passionately debated which class of drugs should be initial therapy for hypertension. Resolution of this issue, which has enormous clinical, public health, and economic implications, comes at a time of intense pressure to reduce health care costs while improving clinical outcomes. In this setting, the ALLHAT results, reported in this issue of THE JOURNAL, are particularly noteworthy, because there is no cost-quality tradeoff; the most effective therapy was also the least expensive.
No takes yet. Share an insight, caveat, or question.
Lawrence J. Appel (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: